Citigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $420

Citigroup upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $340 to $420.

Benzinga · 11/07/2019 11:55

Citigroup upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $340 to $420.